CLOs on the Move

Cullinan Oncology

www.cullinanoncology.com

 
Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan`s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Nabeela Rasheed
Vice President Intellectual Property Profile
Jacquelyn Sumer
Chief Legal Officer Profile

Similar Companies

Ziemer USA INC

Ziemer USA INC is a Wood River, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Artizan Biosciences

Artizan Biosciences, Inc. is a biotechnology company with a mission to restore lives disrupted by inflammatory disease through innovation and advancement of microbiota-targeted therapies. We are leveraging our proprietary IgA-SEQ™ technology platform to distinguish disease-driving bacteria from the intestinal microbiota with the goal of developing new and potentially curative treatments.

Pyramid Biosciences

Pyramid Biosciences is dedicated to discovering and developing targeted therapeutics for a wide range of disorders that are regulated by the tropomyosin receptor kinase (TRK) family.

Singulex

Singulex is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kinnate

Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine.